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Myelin oligodendrocyte glycoprotein (MOG) is an integral mem-
brane protein expressed in CNS oligodendrocytes and outermost
myelin lamellae. Anti-MOG Abs cause myelin destruction (demy-
elination) in animal models of multiple sclerosis (MS); however,
such pathogenic Abs have not yet been characterized in humans.
Here, a method that specifically detects IgG binding to human MOG
in its native, membrane-embedded conformation on MOG-trans-
fected mammalian cells was used to evaluate the significance of
these auto Abs. Compared with healthy controls, native MOG-
specific IgGs were most frequently found in serum of clinically
isolated syndromes (P < 0.001) and relapsing-remitting MS (P <
0.01), only marginally in secondary progressive MS (P < 0.05), and
not at all in primary progressive MS. We demonstrate that epitopes
exposed in this cell-based assay are different from those exposed
on the refolded, extracellular domain of human recombinant MOG
tested by solid-phase ELISA. In marmoset monkeys induced to
develop MS-like CNS inflammatory demyelination, IgG reactivity
against the native membrane-bound MOG is always detected
before clinical onset of disease (P < 0.0001), unlike that against
other myelin constituents. We conclude that (i) epitopes displayed
on native, glycosylated MOG expressed in vivo are early targets for
pathogenic Abs; (ii) these Abs, which are not detected in solid-
phase assays, might be the ones to play a pathogenic role in early
MS with predominant inflammatory activity; and (iii) the cell-based
assay provides a practical serologic marker for early detection of
CNS autoimmune demyelination including its preclinical stage at
least in the primate MS model.
allergic encephalomyelitis  autoimmunity  clinically isolated syndrome 
demyelination
Multiple sclerosis (MS) is an immune-mediated, chronicdemyelinating disorder of CNS white matter mediated by
CD4 myelin-reactive T helper 1 cells (1). Humoral immunity
may play a role in MS pathogenesis, as suggested by intrathecal
Ab synthesis and oligoclonal B cell expansion, observations of
Ab deposition associated with myelin vacuolization in MS
plaques (2), and involvement of IgG and complement deposition
(3). Myelin oligodendrocyte glycoprotein (MOG) is a target
myelin antigen for both humoral and cellular CNS-directed
immune responses. The full-length protein contains 218 aa and
two predicted transmembrane domains, is posttranscriptionally
processed as suggested by apparent electrophoretic mobility, and
is a potential site for glycosylation, phosphorylation, isopreny-
lation, and myristoylation (4). The encephalitogenic properties
of MOG are believed to result from the extracellular location of
its IgV-like domain on the outermost myelin lamellae, which
makes it an exposed target accessible to initial autoimmune
attack on compact myelinated axons (5). In both rodent and
primate MS models of experimental allergic encephalomyelitis
(EAE), Abs against MOG directly induce demyelination (6, 7).
Moreover, certain Abs against MOG have been proposed as
predictors of early conversion to clinically definite MS in the
context of a first demyelinating event (8).
A common problem encountered in human studies of humoral
immunity against MOG is that accurate detection of Ab depends
highly on the conformation of the antigens used for detection.
Previous studies, either in MS or EAE, have not fully charac-
terized the structural features of the proteins used as Ab targets
in vitro and have reported conflicting findings, in part because of
the different folded forms of this poorly water-soluble antigen.
The existing assays detecting anti-MOG Abs use various MOG
preparations, recombinant, native-purified, or in vitro-translated
proteins of variable length including short peptides (4, 8–11).
None of these methods takes into account the specific tertiary
structure of the folded MOG as it is presented to the immune
system in vivo, e.g., in association with a hydrophobic, lipid-rich
bilayer membrane environment. Therefore, these techniques
may fail to detect reactivity against epitopes displayed by native
MOG expressed in situ on myelin sheaths, as it would be upon
an initial immune response.
Here, we describe a cell-based assay that specifically measures
Abs directed against conformationally folded, cell membrane-
expressed human MOG (designated hMOGcme), and evaluate
the relative incidence of these antinative MOG Abs in serum of
humans andCallithrix jacchusmarmosets withMS-like EAE.We
find that hMOGcme Abs predominate during clinically isolated
syndrome (CIS) and relapsing-remittingMS (RRMS) and can be
detected during the preclinical stage of EAE. These findings
underscore the potential value of antinative MOG Abs as a
practical candidate biomarker for detecting MS at its early,
inflammatory stage.
Results
Chinese Hamster Ovary (CHO)-MOG Assay (MOGcme) Validation. Fig. 1
shows high levels of MOGcme expression, as demonstrated by
staining of MOG-transfected CHO cells with the monoclonal
anti-MOGAb 8-18C5. Detection of hMOGcme-specific Abs with
this cell-based assay was sensitive because a concentration of1
ngml of 8-18C5 produced a binding ratio (BR) 1.5 (data not
shown). Staining with a positive control serum (patient 1158) is
shown in Fig. 1C. This control was used in each assay to
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normalize for interassay variability and minimize experimental
errors such as variation in surface expression of MOG. The
mean ( SEM) BR to hMOGcme of this control from nine
independent experiments was 1.96  0.145 (Fig. 1D), and the
interassay coefficient of variation was 22%. The intraassay
coefficient of variation (quadruplicate) was 3.2%. In each assay
analyzing human serum, the binding against nontransfected
CHO (ntCHO) cells was used as background control.
Characterization of Exposed Epitopes of hMOGcme. We analyzed the
binding properties of monoclonal, recombinant marmoset Fab
Ab fragments produced against the nonglycosylated extracellu-
lar domain of recombinant rat MOGaa1–125 (rMOG125). Four
Fabs, designated M3-8, M26, M3-24, and M3-31, were selected
by their ability to recognize rMOG125 in ELISA, and because
they recognize distinct conformationally defined epitopes (12).
TheM3-31 andM26 Fabs strongly stained the MOG-transfected
CHO cells identical to 8-18C5 (0.5 gml) (Fig. 2 A and B). On
the contrary, no binding was observed for the two other Fabs,
M3-24 and M3-8 (Fig. 2 C and D). These results indicate that
very specific epitopes of MOG are expressed on the MOG-
transfected CHO cells and do not overlap with the other epitopes
displayed by rMOG125 on solid ELISA support. The observa-
tion that only three of five monoclonal reagents tested bind to
the transfected cells also renders a nonspecific binding effect
unlikely.
IgG Reactivity in Human Serum. Compared with age-matched
healthy controls (HCs), the titers of IgG directed against mem-
brane-bound hMOGcme were most significantly increased in CIS
(P  0.001). Increased titers were also present in RRMS and
secondary progressive MS (SPMS) subtypes, compared with HC
(P  0.01 and P  0.05, respectively) (Fig. 3). The differences
were also significant when comparing primary progressive MS
(PPMS) with all other subtypes [P  0.001 (CIS), P  0.01
(RRMS), and P  0.05 (SPMS)]. No statistical difference was
found between PPMS and HC (P not significant) or between the
CIS, RRMS, or SPMS subtypes when paired comparisons were
made. No treatment-related difference was found.
IgG Reactivity in Marmoset EAE. Eleven C. jacchus marmosets
immunized with human white matter were tested for plasma
reactivity against hMOGcme on MOG-transfected CHO cells.
For these serial studies, the first time point of Ab detection (i.e.,
serum conversion) was compared with the appearance of the
first clinical signs of EAE. Three animals (U30-00, UO61-02, and
UO53-01) were killed before onset of neurological deficits
(preclinical disease), but exhibited CNS inflammation and
blood-brain-barrier breakdown as demonstrated by cerebrospi-
nal f luid pleocytosis (mean cerebro-spinal f luid mononuclear
cells 173 perl; range 80–340 perl). Serum reactivity against
hMOGcme was consistently detected in the earliest blood sample
obtained after immunization (mean  SD  14  2 days;
range  13–18 days) (Table 1) and was clearly present in each
animal before the appearance of any clinical sign (mean SD
21  9 days; range  16–43 days). The difference between time
of appearance of serum IgG reactivity to hMOGcme and appear-
Fig. 1. Cell-based (hMOGcme) assay. (A and B) Staining of MOG-transfected
CHO cells with anti-MOG Ab 8-18C5 (0.5gml) and detection by FACS (A) and
immunofluorescence (B). (B Inset) Negative control omitting primary Ab. (C)
Positive control patient serum (RRMS 1158, 1:10) displaying a clear shift for
MOG-transfected CHO cells (filled trace) when compared with ntCHO cells
(open trace). (D) Mean BR (BR  SEM) calculated as the Gmean from nine
independent assays.
Fig. 2. Binding characteristics of MOG-specific marmoset recombinant Fab
fragments. Binding of monoclonal Fabs specific for rMOG125 (0.5 gml) by
FACS against hMOGcme. Background is represented by the binding to the
ntCHO cells (open traces) and compared with the binding to MOG-transfected
CHO cells (filled traces). Both Fabs M26 (A) and M3-31 (B) strongly recognize
an epitope displayed on hMOGcme, in contrast to Fabs M3-24 (C) and M3-8 (D).
Fig. 3. Analysis of human serum IgG reactivity against hMOGcme. BR nor-
malized (BRN) is the Gmean value of IgG binding to MOG-transfected CHO
cells divided by that of IgG binding to ntCHO cells, normalized to the value of
the positive control tested in each plate. Horizontal bars  median. See text
for details.









ance of clinical signs was highly significant (P 0.0001) (Fig. 4).
Reactivity was not detected in preimmune plasma.
Comparison of Human IgG Binding on hMOG125 and hMOGcme. The
serum binding characteristics of the CIS cohort (n  36) were
tested by ELISA using recombinant human MOGaa1–125
(hMOG125) and compared with hMOGcme reactivity by FACS on
the MOG-transfected CHO cells. Although some CIS patients
displayed high reactivity against hMOG125, unlike for hMOGcme
reactivity, there was no statistical significant difference between
CIS and HCs (data not shown). By linear regression and
comparison test, results from these two assays showed no
correlation (P not significant), indeed suggesting that different
epitopes are detected by both assays (Fig. 5A).
Specificity of MOG and Differential MOG-Epitope Binding in Human
Serum. To discriminate the epitopes displayed by hMOG125 from
those displayed on hMOGcme on MOG-transfected CHO cells,
we performed a series of preabsorption experiments with two
sera, both representative of early and inflammatory forms of
MS: the positive control used in our cell-based assay (RRMS
1158) and a CIS patient displaying a high reactivity to both
hMOGcme and hMOG125 (CIS 008). Preabsorption against
ntCHO cells served as control in the hMOGcme assay (FACS of
MOG-transfected CHO cells), and preabsorption against 1%
BSA served as a control for the hMOG125 ELISA assay. Com-
pared with these controls, preabsorption of either sample on
hMOG125 did not affect hMOGcme reactivity. Preabsorption on
hMOGcme resulted in a decrease in BR (31% for CIS 008 and
24% for RRMS 1158), when tested with hMOGcme expressed on
the MOG-transfected cells (Fig. 5B). Similarly, when tested on
hMOG125, no change in reactivity occurred when samples were
preabsorbed on the MOG-transfected cells (hMOGcme). On the
contrary, the samples preabsorbed on hMOG125 displayed a
decrease in BR, by 21% and 57%, respectively, when tested on
hMOG125 (Fig. 5C). These experiments unequivocally demon-











UO62–02 43 97 3 (84) 18
UO50–01 21 86 2 (57) 14
UO50–00 21 78 3 (38) 14
UO52–01 21 52 3 (40) 18
UO25–00 21 61 2 (57) 14
UO57–02 32 82 1.5 (73) 18
UO21–99 18 23 1.5 (23) 13
UO23–00 16 31 2 (28) 15
UO30–00 Preclinical 23 0 13
UO61–02 Preclinical 31 0 14
UO53–01 Preclinical 38 0 16
Median  SD 21  9 52  28 2  1 (49  22) 14  2
dpi, day postimmunization.
Fig. 4. Time course of serum IgG directed against hMOGcme in marmoset
EAE. Results are from 11 EAE C. jacchus marmosets immunized with human
white matter, 3 of which were killed before onset of clinical disease. First
occurrence of serum IgG directed against hMOGcme is compared with time of
clinical onset of EAE in a Kaplan–Meier survival plot. Please see text and Table
1 for details.
Fig. 5. Selective epitope presentation on hMOGcme. (A) Binding to hMOG125 by
ELISA compared with binding to hMOGcme by FACS in the CIS cohort (n 36). By
linear regression analysis, there is no correlation between the results of these two
methods (P not significant, r2  0.00023, Spearman r; straight line is the linear
regression curve; dotted line indicates 95% confidence interval) even when clear
serum reactivity is present in both assays. BRN, BR normalized. (B and C) Preab-
sorption of serum on either hMOGcme (Left) or hMOG125 (Right), followed by
testing by FACS (B, hMOGcme) or ELISA (C, hMOG125). Preabsorption on hMOG125
or hMOGcme only altered the reactivity in the corresponding system of detection.
See Materials and Methods for additional details.
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strate that hMOGcme and hMOG125 display separate epitopes of
the MOG protein.
Discussion
Methods to study Ab reactivity to MOG (ELISA, Western blot,
liquid-phase assay) commonly use linear peptides, polypeptide,
or partially refolded glycosylatedMOG. The exact conformation
of MOG displayed in these assay systems is difficult to assess and
control and may result in the display of some, or partially,
aberrant MOG epitopes that are not exposed under physiolog-
ical conditions in vivo. The disease relevance of these Abs is
therefore uncertain, as apparent from somewhat conflicting
results in previous reports (2, 8–11, 13–16). We show here that
Abs against native glycosylated MOG expressed on mammalian
cells are commonly detected in MS serum with high sensitivity
(1 ng). Specificity is established by the selective binding of
three of five monoclonal anti-MOG Abs tested in this system
(murine 8-18C5 and marmoset Fabs M3-31 and M26). Thus, as
is the case for these mAbs (9, 12, 13) the hMOGcme assay
measures Abs that bind to conformational epitopes of MOG.
Our results show that there is no correlation in the CIS cohort
between serum reactivity against hMOG125 (solid-phase ELISA)
and hMOGcme (MOG-transfected CHO cells), and preabsorp-
tion demonstrates that there is no cross-reactivity between
epitopes of MOG displayed in these two different assays (Fig. 5).
This finding also argues, along with the significant signal quench-
ing in the cell-based assay achieved only by preabsorption on
hMOGcme (MOG-transfected cells), and not by preabsorption
on either hMOG125 or ntCHO cells, against a nonspecific
‘‘sticky’’ effect of MS serum. The hMOGcme assay is unique
because it allows the testing of IgG reactivity directed against
epitopes presented by the native glycosylated and conforma-
tional structure of MOG as it is expressed on intact myelin
sheath or oligodendrocytes and subject to membrane lipid–
protein interactions, which have been shown to be critical for
maintenance of myelin structure and epitope exposure (17).
Analysis of reactivity against hMOGcme on the MOG-
transfected CHO cells in the different MS clinical subtypes
showed a very prominent response in CIS, RRMS, and to a lesser
degree SPMS, compared with HC and PPMS. There is therefore
a humoral immune response specifically directed against intact
MOG expressed on myelin oligodendrocytes in those groups of
patients. The predominance of hMOGcme-specific Abs in CIS
suggests that these Abs represent early stages of the immune
response against intact (as opposed to degraded) myelin, and
thus may represent a marker of inflammatory phases of disease
related to blood-brain-barrier opening andor molecular mim-
icry. Our results are in partial agreement with a recent report
showing an increase of Ig response directed against ex vivo
glycosylated-native-MOG in first demyelinating events (14).
RRMS is the most common MS subtype that includes 85% of
the patients at initial presentation. The secondary progressive
pattern is known to follow RRMS in 50% of the cases after 10
years of disease activity (18, 19). Thus, these two subtypes might
be considered as a continuous process starting with a common
pathophysiological origin. Although we did not include a group
of other neurological disorders in the current study, we have
compared MS clinical subtypes among themselves and clearly
demonstrated that the hMOGcme-specific Ab response is re-
stricted to early forms. It is of importance to note that the PPMS
cohort does not show elevated serum IgG against hMOGcme and
that significant differences in antibody status also exist between
SPMS and PPMS, which implies that the serum level of these Abs
or lack thereof is not solely related to a progressive course of
disease. The HC subjects were age-matched with the CIS group,
indicative that the heightened response in CIS is disease-specific
and not related to a younger age in this cohort. The lack of
heightened Ab responses against hMOGcme in PPMS is in
contrast with the increased IgG reactivity against recombinant
rMOG125 and against neurons in this disease subtype (unpub-
lished data and ref. 20). Abs against galactocerebroside, the
major myelin glycolipid, are not found in PPMS but are associ-
ated mostly with established relapsing-remitting and secondary-
progressive forms (21). It is thus becoming increasingly apparent
that Ab responses against myelin antigens may follow patterns
that reflect a combination of underlying cause, antigen exposure,
and secondary immune responses. These patterns of humoral
reactivity, rather than a classification based on clinical criteria
(RRMS, SPMS, or PPMS) can be exploited to refine our
understanding of disease stage, cause, and prognosis.
The high prevalence of hMOGcme-reactive Abs in CIS, i.e.,
contemporary of the first clinically apparent event for MS, is in
sharp contrast to other antimyelin Abs, such as those directed
against glycolipids that predominate in establishedMS (21). This
observation has two important implications: first, it suggests that
hMOGcme-reactive Abs may be implicated in the early patho-
genesis of disease. Engagement of membrane-embedded MOG
by the mAb 8-18C5, which as shown in the current study binds
hMOGcme with a high affinity, has been shown to induce MOG
phosphorylation in oligodendrocytes, leading to pronounced
morphological changes with potentially demyelinating effects
(22). Second, andor alternatively, our findings also suggest that
hMOGcme-reactive Abs may be useful to help diagnose MS at its
earliest stages. To consolidate this contention, the hMOGcme
assay was used to study the time course of the Ab response
against hMOGcme in marmoset EAE induced by immunization
with human white matter. In these animals, serum reactivity
against hMOGcme was always detected before clinical onset,
contrary to anti-myelin basic protein and antigalactocerebroside
Abs that occur at later stages (21). Because the immunizing
antigen contained native MOG similar in conformation to
hMOGcme, these findings imply that the hMOGcme-reactive Abs
are the ones that initiate andor first result from active demy-
elination. Regardless of whether they are causative or not,
hMOGcme-reactive Abs clearly represent a valuable biomarker
for disease activity and, at least in the MS model, subclinical
disease.
It is of great interest to note that the marmoset Fabs M3-31
andM26, which were obtained from an animal with overt clinical
signs of EAE immunized with rMOG125 and had an established
anti-MOG Ab response, are the only ones among those tested
that recognize hMOGcme. In our previous studies of human MS,
using a highly specific competition assay between human serum
IgG andmarmoset Fabs we found that FabsM3-24 andM3-8 can
compete with serum IgG from patients with established MS, but
we have so far not been able to demonstrate any competition
between human IgGs and either M3-31 or M26 (12). Although
further studies are needed to examine whether IgG purified from
patients with a CIS does compete with Fabs M3-31 and M26,
these data suggest that the epitopes defined by these two Fabs
are the ones targeted by early humoral responses in MS, whereas
the ones defined by M3-8 and M3-24 may be part of the Ab
response at a later stage.
Taken together, our results strongly suggest that analogous to
certain serologic markers that are predictive of type I diabetes
(23) anti-hMOGcme Abs could be used in humans as a biomarker
to diagnose MS or MS risk. Further studies are needed to
validate this biomarker and understand the benefits and infor-
mation that in combination with other Ab profiling techniques
(8, 21) it could provide to scientists, treating neurologists, and
individuals with suspected or established MS.
Materials and Methods
Patients. Ninety-two patients with clinically definite MS (Poser
criteria) (24), 36 patients with CIS, and 37 HCs were recruited
from the University of California, San FranciscoMS Center, and









theMSCenter of Pamplona, Spain (CIS). All investigations were
conducted according to the Declaration of Helsinki. Blood was
obtained by venipuncture after informed consent in full com-
pliance with the Institutional Review Board, and clotted serum
was stored at40°C until use. Patients were classified as RRMS
(n  35), SPMS (n  33), and PPMS (n  24) MS by clinical
history (24). A CIS was defined by a first clinical event indicative
of demyelination with no history of previous neurological symp-
tom. Age, gender, disease duration, and disability state [Ex-
panded Disability Status Score (EDSS) (25)] were recorded at
time of sampling. HCs were chosen to match sex and age of the
CIS group. The median age, disease duration, and EDSS were
higher for the SPMS group than for the RRMS and CIS groups
(Table 2). All RRMS and 1933 SPMS patients were treated
with IFN-. Two of the PPMS patients were treated with
mitoxantrone and monthly pulsed steroids.
Animals. C. jacchusmarmosets were cared for in accordance with
the guidelines of the Institutional Animal Care and Usage
Committee. EAE was induced by immunization with 100 mg of
human white matter, which contains native, membrane-
embeddedMOGhomogenized in complete Freund’s adjuvant as
described (26). Plasma was obtained from EDTA-anticoagu-
lated blood at baseline and 2- to 4-week intervals and stored at
40°C. The animals were scored every other day for the
development of clinical signs by using a published scale (27).
Preparation of MOG-Transfected Cells. CHO cells were transfected
with a full-length construct corresponding to the major -1 form
of human MOG as described (28). CHO cells were cultured in
T-225 flasks (Costar), in RPMImedium 1640 supplemented with
10% FCS, 1 Glutamax, 1 mM sodium pyruvate, and 50 gml
gentamycine. G418 (500 gml, GIBCO) was added to the
medium of transfected cells. Stable surface expression of MOG
was verified by immunofluorescence and FACS on transfected
cells after multiple passes and washes; cells were used for flow
cytometry (FACS) assay when a confluence of 80–90% was
reached. To check for surface expression of hMOGcme, 3  104
MOG-transfected CHO cells were deposited on a slide and fixed
with 100% methanol for 5 min at 20°C. After blocking with
PBS containing 2% BSA and 2% FCS for 30 min, cells were
incubated 1 h at 37°C with the mouse monoclonal anti-MOG Ab
8-18C5 (5 gml, gift of C. Linington, University of Aberdeen,
Aberdeen, Scotland). Fluorescence was revealed after 1-h incu-
bation at 37°C by a goat anti-mouse IgG FITC Ab (Sigma) and
examined under a fluorescence microscope (Nikon Eclipse
E600). Negative controls were done with secondary Ab alone.
Serum IgG Reactivity. Cells were trypsinized, diluted in FACS
buffer (PBS, 0.1% Na azide, and 2% FCS), and plated in a
96-well plate (Costar) at a density of 200,000 per well. After
blocking in FACS buffer containing 10% FCS for 15 min at 4°C,
cells were washed and human serum (1:10) was added for 1-h
incubation at 4°C. After washing, cells were incubated with a
goat anti-human IgG FITC (Caltag, South San Francisco, CA)
at the recommended concentration for 30 min at 4°C. After a
final wash, cells were resuspended in FACS buffer containing
propidium iodide (Molecular Probes) at 2 gml and gently
shaken. Samples were kept on ice and analyzed by gating the
selected live cell population (104 cells) within 1 h of harvesting
by trypsinization. Each FACS experiment included an internal
positive control consisting of the monoclonal anti-MOG 8-18C5
Ab (0.5 gml) and rabbit anti-mouse FITC (DAKO) as sec-
ondary Ab. For each sample, the geometric mean intensity
(Gmean) of FITC (WINMDI 2.8 software) was measured for
MOG-transfected CHO cells and compared with that of ntCHO
cells. The BR was calculated as the Gmean forMOG-transfected
CHO cells divided by the Gmean for ntCHO. To compare
different assays, for each sample the BR was normalized to that
of a human positive control (RRMS 1158) included in each
experiment.
For studies in marmosets, MOG-transfected CHO cells were
incubated for 1 h at 4°C with marmoset serum diluted 1:100.
FITC-conjugated Ab against whole monkey IgG (Sigma) diluted
at 1:100 was used as secondary Ab and incubated 30 min at 4°C.
FACS analysis was performed as described above. IgG binding
against hMOGcme was considered positive when the BR (Gmean
preimmunizationGmean time point tested) was 1.5.
Differential Reactivity of Monoclonal Fab Fragments. Recombinant
Fabs were derived from a C. jacchus marmoset immunized with
rMOG1–125 produced in Escherichia coli (rMOG125) (12). Fabs
were diluted in FACS buffer at 0.5 gml and added to ntCHO
or MOG-transfected CHO cells. FITC-conjugated Ab against
whole monkey IgG (Sigma) diluted at 1:100 was used as sec-
ondary Ab for 30 min at 4°C. FACS was performed as described
above.
ELISA Assay. hMOG125 expressed in E. coli was coated overnight
on polystyrene microtiter plates at 0.5 g per well (Maxisorb,
Nunc). After washing and blocking with 1% BSA in PBS 
0.05% Tween (BSA-PBS-T) for 2 h at room temperature, sera
(1:200) were diluted in BSA-PBS-T and added to the plate. Ab
binding was detected by an alkaline phosphatase AP-labeled
goat-anti-human IgG (Sigma) for 1 h at room temperature.
Plates were developed with para-nitrophenyl phosphate (Moss,
Pasadena, MD) for 30 min in the dark at room temperature and
read at 405 nm in a microplate reader (SpectraMax, Molecular
Devices). Results were expressed as BR, i.e., signal over BSA
background.
Preabsorption of Sera on hMOGcme and hMOG125. To further validate
the cell-based assay and eliminate the possibility of nonspecific
binding effects from either MS serum or transfection proce-
dures, we conducted binding experiments after preincubation of
serum with the respective antigens. For hMOGcme preabsorp-
tion, 5 106 MOG-transfected CHO cells and ntCHO cells were
separately incubated with serum diluted 1:10 for 1 h at room
temperature with gentle agitation. After centrifugation at 900
g for 2 min, supernatant were collected and preabsorption was












CIS 36 2412 32 (18–49) 0.3 (0.1–3) 2 (0–4)
RRMS 35 2114 41 (19–61) 2.4 (0.6–22.2) 2.5 (0–6.5)
SPMS 33 1914 46 (36–60) 11 (2–32) 6 (2.5–8.5)
PPMS 24 1608 54 (40–65) 6.3 (0.8–18.8) 4.5 (2.5–8)
HC 37 2413 35 (21–63) — —
EDSS, expanded disability status scale (25).
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repeated three times in total with fresh cells. After the final
preabsorption, supernatants were centrifuged at 3,600  g for 5
min and collected for subsequent experiments.
For hMOG125 preabsorption, ELISA plates were coated with
either 1g BSA or 0.5g hMOG125 overnight and blocked in 1%
BSA in PBS plus 0.05% Tween for 2 h, then sera were incubated
1 h. Supernatants were collected and preabsorption was re-
peated eight times in total with fresh hMOG125. After the final
preabsorption step, supernatants were collected as above.
Data Analysis. Statistical analyses were performed by using
Kruskal–Wallis with Dunn’s post hoc test for multiple compar-
isons for interpatient group differences. Interassay correlation
was analyzed with Spearman r correlation. Survival analysis for
time-dependent variables was assessed by Kaplan–Meyer anal-
ysis and the Cox proportional hazard model (PRISM 3.0).
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